Return on investment in science: twenty years of European Commission funded research in Alzheimer's dementia, breast cancer and prostate cancer.
Alzheimer's disease (AD), breast cancer (BC) and prostate cancer (PC) continue to be high in the research and innovation agenda of the European Commission (EC). This is due to their exceptionally large burden to the national health systems, the profound economic effects of opportunity costs attribut...
| Publicado en: | Cost Effectiveness & Resource Allocation Vol. 22; no. 1; pp. 1 - 25 |
|---|---|
| Autores principales: | , , , , , , , , , |
| Formato: | pictorial research tables/charts Journal Article |
| Publicado: |
BioMed Central
6/16/2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |